Istradefylline (Nourianz) for Parkinson ' s Disease
Date: February 10, 2020
Issue #:
1591Summary:
The FDA has approved istradefylline (Nourianz—
Kyowa Kirin), an oral adenosine A2A receptor antagonist,
for use as an adjunct to carbidopa/levodopa in adults
with Parkinson ' s disease (PD) who experience " off "
episodes. Istradefylline is the first adenosine A2A
receptor antagonist to be approved in the US; it has
been available in Japan since 2013.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Source Type: research